September 19, 2006 Re: Collaboration and License Agreement dated as of August 1, 2006 by and between POZEN INC. and Astrazeneca AB (the "Collaboration Agreement") Dear Denise:
EXHIBIT
10.2
September
19, 2006
Re:
Collaboration and License Agreement dated as of August 1, 2006 by and between
POZEN INC. and Astrazeneca AB (the "Collaboration Agreement")
Dear
Xxxxxx:
This
letter sets forth the understanding between POZEN INC. (“POZEN”) and Astrazeneca
AB (“Astrazeneca”) with regard to the matters set forth below and in connection
with the Collaboration Agreement. Any capitalized terms not otherwise defined
herein shall have the meaning given such term in the Collaboration Agreement.
POZEN and Astrazeneca herein are collectively referred to as the Parties.
1. In
accordance with Section 12.1 of the Collaboration Agreement, the Effective
Date
of the Collaboration Agreement is September 7, 2006.
2. The
Parties have attached hereto final versions of Schedule 10.1 and Schedule 10.7,
which shall be incorporated by this reference and made part of the Collaboration
Agreement.
3. The
Parties agree that a final schedule of Formulation Development Activities and
a
Formulation Budget pursuant to Section 6.1.4 of the Collaboration Agreement
shall be agreed by the Parties as soon as reasonably practicable but not later
than *****.
4. This
letter is being executed pursuant to the terms of Section 15.6 of the
Collaboration Agreement and shall be governed by the general terms of Article
15
of the Collaboration Agreement. Except as otherwise expressly provided in this
letter, the terms of the Collaboration Agreement shall remain in full force
and
effect. This letter may be executed in counterparts, each of which when so
executed and delivered shall be an original, and all of which together shall
constitute one instrument.
*****
Portion for which confidential treatment requested.
If
this
letter reflects your understanding, please countersign in the space provided
below and return one original copy to POZEN by facsimile at (000) 000-0000.
Regards,
________________________
Xxxx
X.
Xxxxxxxxx
Chairman,
President and CEO
AGREED:
ASTRAZENECA
AB (publ)
|
By:
|
|
|
Name:
|
Xxxxxx
Xxxxx
|
|
Title:
|
Licensing
Director
|
*****
Portion for which confidential treatment requested.
-
2
-
SCHEDULE
10.1
Part
10.1.14 - Agreements
|
Consultant/Vendor
|
Form
of Contract
|
Service
Description
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
|
*****
|
*****
|
*****
|
*****
Portion for which confidential treatment requested.
-
3
-
SCHEDULE
10.7
POZEN
SUBCONTRACTORS
*****
If
AstraZeneca provides POZEN with written notice describing in reasonable detail
information that has reasonably and in good faith caused AstraZeneca to believe
that it would not be in the best interest of the Product for POZEN to enter
into
any new subcontract with any of the subcontractors listed above, then POZEN
will
not, without AstraZeneca’s prior written consent (not to be unreasonably
withheld) engage such subcontractor in the conduct of Development activities
under the Agreement.
301264
v2/RE
*****
Portion for which confidential treatment requested.
-
4
-
